Trial Profile
Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension?
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Bisoprolol (Primary) ; Candesartan cilexetil (Primary) ; Doxazosin (Primary) ; Isosorbide mononitrate (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms ROTATION
- 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 20% to 23%.
- 31 May 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.